⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514226 | 1.00 | — | — | |
| Bicarbonate SCHEMBL28609581 | 0.87 | GAA (0.42) | — | |
| SCHEMBL360577 | 0.79 | — | — | |
| SCHEMBL29571714 | 0.79 | — | — | |
| SCHEMBL3942156 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL581311 | 0.77 | — | — | |
| SCHEMBL11690799 | 0.77 | CDC25B (0.41) | — | |
| SCHEMBL31145055 | 0.75 | — | — | |
| SCHEMBL952595 | 0.75 | — | — | |
| SCHEMBL1203743 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4584266-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4534528-A1 | NOVEL SULFANONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119604487-A | Novel sulfimide derivative or pharmaceutically acceptable salt thereof and application thereof | 韩国科学技术研究院 | 2025-03-11 | — | — | CN | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240417405-A1 | Substituted Spiro Derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-19 | — | — | US | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240262807-A1 | COMPOUND USED AS BCR-ABL INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| WO-2015196014-A1 | PARASITICIDAL COMPOSITIONS COMPRISING INDOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015107494-A1 | 1 -(TRIAZIN-3-YI_/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015031824-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015031824-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014202827-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2014-12-24 | — | — | WO | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2414340-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-4052508-A | TRANQUILIZER, MUSCLE RELAXANT, ANTICONVULSANT, ANTIPARKINSON | MERCK & CO., INC. (US) | 1977-10-04 | — | — | US | disclosed |